{"url_path":"/sec/pure/8-k/2026-02-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-20","source_url":"https://www.sec.gov/Archives/edgar/data/1006028/0001493152-26-007616-index.html","accession_number":"0001493152-26-007616","cik":"0001006028","ticker":"PURE","issuer_name":"PURE BIOSCIENCE, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006028/0001493152-26-007616-index.html","primary_entity_key":"0001006028","primary_entity_name":"PURE BIOSCIENCE, INC."},"word_count":530,"has_tables":true,"body_markdown":"**Item\n5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\nPure\nBioscience, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on February 17,\n2026. Of the 111,886,485 shares of the Company’s common stock outstanding as of the record date, 73,820,863 shares, or 65.97%,\nwere represented at the Annual Meeting either in person or by proxy.\n\n \n\nA\ndescription of each matter voted upon at the Annual Meeting is described in detail in the Proxy Statement. The number of votes cast “For”\nand “Withheld” and “Against” and the number of “Abstentions” and “Broker Non-Votes” with\nrespect to each matter voted upon are set forth below.\n\n \n\n(1)\nElection of Directors. The Company’s stockholders elected each of Tom Y. Lee, CPA, Ivan Chen, Tom Myers, David M. Rendall, Robert\nBartlett, Bernard Blotner and Darin Zehr with the approval of 97.82%, 98.07%, 96.52%, 96.83%, 96.55%, 96.85% and 96.86%, of the votes\ncast, respectively, to hold office until next year’s Annual Meeting of Stockholders and until their respective successors are elected\nand qualified. The following table shows the tabulation of the votes cast For and Withheld with respect to the election of each of the\ndirector nominees as well as the Broker Non-Votes submitted for each director nominee:\n\n \n\nDirector \nFor  \nWithheld  \nBroker\nNon-Votes \n\nTom Y. Lee, CPA \n 59,860,307  \n 1,332,527  \n 12,628,029 \n\nIvan Chen \n 60,011,852  \n 1,180,982  \n 12,628,029 \n\nTom Myers \n 59,061,293  \n 2,131,541  \n 12,628,029 \n\nDavid M. Rendall \n 59,253,062  \n 1,939,772  \n 12,628,029 \n\nRobert Bartlett \n 59,080,819  \n 2,112,015  \n 12,628,029 \n\nBernard Blotner \n 59,262,655  \n 1,930,179  \n 12,628,029 \n\nDarin Zehr \n 59,273,777  \n 1,919,057  \n 12,628,029 \n\n \n\n(2)\nRatification of Auditors. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A., with the approval\nof 99.81% of the votes cast, as the Company’s independent registered public accounting firm for the fiscal year ending July 31,\n2026. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on\nthis proposal:\n\n \n\nFor\n \nAgainst\n \nAbstentions\n\n73,008,365\n \n137,649\n \n674,849\n\n \n\n(3)\nExecutive Compensation. The Company’s stockholders, on a non-binding, advisory basis, approved the compensation of the Company’s\nnamed executive officers, with the approval of 96.68% of the votes cast, as disclosed in the Proxy Statement. The following table shows\nthe tabulation of the votes cast For and Against this proposal as well as the Abstentions and Broker Non-Votes submitted on this proposal:\n\n \n\nFor\n \nAgainst\n \nAbstentions\n \nBroker\nNon-Votes\n\n58,428,196\n \n2,000,989\n \n763,649\n \n12,628,029\n\n \n\n4)\nAmendment to Certificate of Incorporation. The Company’s stock-holders approved an amendment to our Certificate of Incorporation\nto increase the authorized number of shares of Common Stock from 200,000,000 to 250,000,000 shares, with the approval of 63.87% of the\noutstanding shares of common stock, as disclosed in the Proxy Statement. The following table shows the tabulation of the votes cast For\nand Against this proposal as well as the Abstentions submitted on this proposal:\n\n \n\nFor\n \nAgainst\n \nAbstentions\n\n71,472,843\n \n2,298,269\n \n49,751\n\n \n\nNo\nother items were presented for stockholder approval at the Annual Meeting.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**PURE\nBIOSCIENCE, INC.**\n\n \n \n \n\nDated:\nFebruary 20, 2026\nBy:\n*/s/\nRobert Bartlett*\n\n \n \nRobert\nBartlett\n\n \n \nChief\nExecutive Officer"}